US2992970A - Aqueous sorbitol enema solution and method of using same - Google Patents
Aqueous sorbitol enema solution and method of using same Download PDFInfo
- Publication number
- US2992970A US2992970A US685430A US68543057A US2992970A US 2992970 A US2992970 A US 2992970A US 685430 A US685430 A US 685430A US 68543057 A US68543057 A US 68543057A US 2992970 A US2992970 A US 2992970A
- Authority
- US
- United States
- Prior art keywords
- sorbitol
- solution
- enema
- potassium
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
Definitions
- This invention relates to an aqueous enema solution, and particularly to a solution which is safe for use in cardiac and diabetic patients.
- Enemas are used to evacuate the bowel of patients or to prepare patients for sigmoidoscopic examination.
- a large volume of soap solution has usually been used. The large volume causes discomfort to the patient and the soap often irritates the mucous membrane.
- a relatively small volume of hypertonic sodium phosphate solution has been used.
- Such concentrated salt solutions may burn or sting if fissures, open hemorrhoids, or other anal pathologies exist.
- Other constituents, which may increase the effectiveness of the enema solutions have only limited solubility in the concentrated salt solutions.
- a dangerous amount of sodium may be absorbed by patients, who because of heart conditions or renal impairment are on a low-sodium diet.
- the object of this invention is to provide an inexpensive, effective, evacuant enema solution having a minimum of contraindications.
- Another object of the invention is to provide an effective, sodium-free enema solution.
- Another object of the invention is to provide an enema solution which will not burn or irritate the rectal mucosa, or openings therein.
- the enema solution of this invention does not cause irritation or burning of fissures or other open places in the rectal mucosa. Moreover, it may be used by patients with cardiac or renal impairment and in diabetic patients. Adequate quantities of a fecal softening agent, such as a salt of dioctyl sulfosuccinic acid, and of a preservative, such as a mixture of methyl and propyl parabens or potassium benzoate, can be dissolved in the enema solution.
- a fecal softening agent such as a salt of dioctyl sulfosuccinic acid
- a preservative such as a mixture of methyl and propyl parabens or potassium benzoate
- the preferred softening agent is potassium dioctyl sulfosuccinate. Concentrations of 0.03 to 0.5 are effective, with 0.1% being preferred. The higher concentrations of potassium dioctyl sulfosuccinate are used for more dilute sorbitol solutions and the lower concentrations for more concentrated solutions.
- this enema solution forms a stable foam.
- This foam interferes with preparation and filling of the solution.
- the foam interferes with rectal examination, or may cause the patient to have gas pains. It may therefore be desirable to add a defoamer, preferably of the silicone type. Methylpolysiloxane has been found particularly effective in concentrations of 0.2 to ppm.
- the enema solution of this invention may be sterilized by heat. Preferably, however, it contains a preservative, such as 0.03 to 0.3% of a salt of benzoic acid. Potassium benzoate is preferred but other benzoates may also be used. Parahydroxy benzoates (parabens) may also be used. A combination of 0.15% methyl para- 2,992,970 Patented July 18, 1961 Example 1 Sorbitol kilograms 25 Potassium dioctyl sulfosuccinate grams Potassium benzoate do 100 istilled Water, quantity to makelOO liters.
- Stoichiometn'c quantities of benzoic acid and potassium hydroxide are dissolved in 40 liters of water giving a pH of approximately 5.3. The desired amount of sorbitol is then added as the 70% solution. The potassium dioctyl sulfosuccinate is dissolved in water to form an 0.5% solution and added to the mixture. Distilled water is added to the final desired volume of 100 liters.
- Sorbitol, dioctyl sulfosuccinate and sodium benzoate are dissolved in 40 liters of water and the pH adjusted to 5.3.
- the methylpolysiloxane solution is added and distilled water added to a final volume of 100 liters.
- Example 4 Sorbitol kilograms 20 Potassium dioctyl sulfosuccinate grams 150 Potassium benzoate do 500 Methylpolysiloxane do 1 Distilled Water, quantity to make 100 liters.
- the solution of sorbitol, dioctyl sulfosuccinate and potassium benzoate is made up as in Example 1.
- the methylpolysiloxane is added as an emulsion in a nontoxic emulsifying agent.
- the mixture is diluted to 100 liters with distilled water.
- An aqueous evacuant enema solution containing 15 to 35% by weight of sorbitol and a nontoxic salt of dioctyl sulfosuccinic acid in distilled water.
- a sodium-free, aqueous evacuant enema solution comprising: 15 to 35 sorbitol; 0.03 to 0.5 potassium dioctyl sulfosuccinate; .2. to 10 ppm. methylpolysiloxane; and 0.03 to 0.3% potassium benzoate.
- An aqueous evacuant enema solution comprising:
- a sodium-free, aqueous evacuant enema solution comprising: about 25 sorbitol; 0.1% potassium dioctyl sulfosuccinate; 0.1% potassium benzoate; 10 ppm. methylpolysiloxane; and having a pH of substantially 5.3.
- An aqueous evacuant enema solution comprising: about 25% sorbitol; 0.1% of a nontoxic salt of dioctyl sulfosuccinic acid; and having a pH of substantially 5.
- An aqueous evacuant enema solution comprising: 15 to 35% sorbitol; 0.03 to 0.5% potassium dioctyl sulfosuccinate; 0.2 to 10 p.p.m. of a methylpolysiloxane defoamer; 0.05 to 0.25% methyl parahydroxybenzoate and 0.01 to 0.05% propyl parahydroxybenzoate.
- a sodium-free, aqueous evacuant enema solution comprising: about 25% sorbitol; 0.1% potassium dioctyl sulfosuccinate; 0.15% methyl parahydroxybenzoate; 0.03% propyl parahydroxybenzoate; 10 ppm. methylpolysiloxane; and having a pH of substantially. 5.3.
- the process of evacuating a human patient which comprises introducing into the rectum of said patient an aqueous solution containing from 15 to 35 sorbitol.
- Wilson J.A.M.A., vol. 158, No. 4, pages 261-263, May 28, 1955.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Description
United States Patent D 2,992,970 AQUEOUS SORBITOL ENEMA SOLUTION AND METHOD OF USING SAME Victor H. Baptist, Burbank, and Arthur Cherkin, Los
'Angeles, Calif., assignors to Don Baxter, Inc., Glendale, Calif., a corporation of Nevada No Drawing. Filed Sept. 23, 1957, Ser. No. 685,430
10 Claims. (Cl. 167--50) This invention relates to an aqueous enema solution, and particularly to a solution which is safe for use in cardiac and diabetic patients.
Enemas are used to evacuate the bowel of patients or to prepare patients for sigmoidoscopic examination. In the past, a large volume of soap solution has usually been used. The large volume causes discomfort to the patient and the soap often irritates the mucous membrane. More recently, a relatively small volume of hypertonic sodium phosphate solution has been used. Such concentrated salt solutions may burn or sting if fissures, open hemorrhoids, or other anal pathologies exist. Other constituents, which may increase the effectiveness of the enema solutions, have only limited solubility in the concentrated salt solutions. Moreover, a dangerous amount of sodium may be absorbed by patients, who because of heart conditions or renal impairment are on a low-sodium diet.
The object of this invention is to provide an inexpensive, effective, evacuant enema solution having a minimum of contraindications.
Another object of the invention is to provide an effective, sodium-free enema solution.
Another object of the invention is to provide an enema solution which will not burn or irritate the rectal mucosa, or openings therein.
We have found that a 25% (weight/volume) sorbitol solution is efiective as an evacuant enema. Concentrations of sorbitol as high as 40% are effective. Concentrations of sorbitol as low as 15% may be used. The solutions of 35 to 40% tend to be sticky, however, and this causes diificulty during sigmoidoscopic examination. The preferred range is therefore l5-35% by weight of sorbitol. One hundred twenty cc. of solution is usually used, although the volume may vary from 100 to 140 cc.
The enema solution of this invention does not cause irritation or burning of fissures or other open places in the rectal mucosa. Moreover, it may be used by patients with cardiac or renal impairment and in diabetic patients. Adequate quantities of a fecal softening agent, such as a salt of dioctyl sulfosuccinic acid, and of a preservative, such as a mixture of methyl and propyl parabens or potassium benzoate, can be dissolved in the enema solution.
The preferred softening agent is potassium dioctyl sulfosuccinate. Concentrations of 0.03 to 0.5 are effective, with 0.1% being preferred. The higher concentrations of potassium dioctyl sulfosuccinate are used for more dilute sorbitol solutions and the lower concentrations for more concentrated solutions.
Under some conditions this enema solution forms a stable foam. This foam interferes with preparation and filling of the solution. Also, when the enema is administered to a patient, the foam interferes with rectal examination, or may cause the patient to have gas pains. It may therefore be desirable to add a defoamer, preferably of the silicone type. Methylpolysiloxane has been found particularly effective in concentrations of 0.2 to ppm.
The enema solution of this invention may be sterilized by heat. Preferably, however, it contains a preservative, such as 0.03 to 0.3% of a salt of benzoic acid. Potassium benzoate is preferred but other benzoates may also be used. Parahydroxy benzoates (parabens) may also be used. A combination of 0.15% methyl para- 2,992,970 Patented July 18, 1961 Example 1 Sorbitol kilograms 25 Potassium dioctyl sulfosuccinate grams Potassium benzoate do 100 istilled Water, quantity to makelOO liters.
Stoichiometn'c quantities of benzoic acid and potassium hydroxide are dissolved in 40 liters of water giving a pH of approximately 5.3. The desired amount of sorbitol is then added as the 70% solution. The potassium dioctyl sulfosuccinate is dissolved in water to form an 0.5% solution and added to the mixture. Distilled water is added to the final desired volume of 100 liters.
Example 2 Sorbitol kilograms 40 Potassium dioctyl sulfosuccinate grams 50 Methyl parahydroxybenzoate do Propyl parahydroxybenzoate do 30 Distilled water, quantity to make 100 liters.
Approximately 50 liters of water are placed in a tank, heated, and the methyl and propyl parahydroxybenzoates dissolved. The sorbitol is then added as the 70% solution. The potassium dioctyl sulfosuccinate is dissolved in water to form an 0.5 solution, and added to the mixture. The pH is adjusted to 5.3 with benzoic acid.
Example 3 Sorbitol kilograms 15 Sodium dioctyl sulfosuccinate "grams" 500 Sodium benzoate do 100 30% solution of methylpolysiloxane do 34 Distilled water, quantity to make 100 liters.
Sorbitol, dioctyl sulfosuccinate and sodium benzoate are dissolved in 40 liters of water and the pH adjusted to 5.3. The methylpolysiloxane solution is added and distilled water added to a final volume of 100 liters.
Example 4 Sorbitol kilograms 20 Potassium dioctyl sulfosuccinate grams 150 Potassium benzoate do 500 Methylpolysiloxane do 1 Distilled Water, quantity to make 100 liters.
The solution of sorbitol, dioctyl sulfosuccinate and potassium benzoate is made up as in Example 1. The methylpolysiloxane is added as an emulsion in a nontoxic emulsifying agent. The mixture is diluted to 100 liters with distilled water.
We claim:
1. An aqueous evacuant enema solution containing 15 to 35% by weight of sorbitol and a nontoxic salt of dioctyl sulfosuccinic acid in distilled water.
2. A sodium-free, aqueous evacuant enema solution comprising: 15 to 35 sorbitol; 0.03 to 0.5 potassium dioctyl sulfosuccinate; .2. to 10 ppm. methylpolysiloxane; and 0.03 to 0.3% potassium benzoate.
3. An aqueous evacuant enema solution comprising:
sorbitol; potassium dioetyl sulfosuccinate; a methylpolysiloxane; and a preservative.
4. A sodium-free, aqueous evacuant enema solution comprising: about 25 sorbitol; 0.1% potassium dioctyl sulfosuccinate; 0.1% potassium benzoate; 10 ppm. methylpolysiloxane; and having a pH of substantially 5.3.'
5. An aqueous evacuant enema solution comprising: about 25% sorbitol; 0.1% of a nontoxic salt of dioctyl sulfosuccinic acid; and having a pH of substantially 5. 3.
6. An aqueous evacuant enema solution comprising: 15 to 35% sorbitol; 0.03 to 0.5% potassium dioctyl sulfosuccinate; 0.2 to 10 p.p.m. of a methylpolysiloxane defoamer; 0.05 to 0.25% methyl parahydroxybenzoate and 0.01 to 0.05% propyl parahydroxybenzoate.
7. A sodium-free, aqueous evacuant enema solution comprising: about 25% sorbitol; 0.1% potassium dioctyl sulfosuccinate; 0.15% methyl parahydroxybenzoate; 0.03% propyl parahydroxybenzoate; 10 ppm. methylpolysiloxane; and having a pH of substantially. 5.3.
8. A ready-to-use, aqueous evacuant enema solution containing 15 to 35% by weight of sorbitol in distilled water and a nontoxic salt of dioctyl sulfosuccinic acid, said salt of sulfosuccinic acid being present in a concen- 10. The process of evacuating a human patient which comprises introducing into the rectum of said patient an aqueous solution containing from 15 to 35 sorbitol.
References Cited in the file of this patent UNITED STATES PATENTS I Hardie Oct. 25,1955
OTHER REFERENCES Chem. Abst., vol. 43, page 6815b, 1949.
Wilson: J.A.M.A., vol. 158, No. 4, pages 261-263, May 28, 1955.
Modern Drug Encyclopedia, 6th Ed., pages 436 and 437, 1955.
U.S. Dispensatoiy, 25th Ed., pages 1764, 1302 and
Claims (1)
1. AN AQUEOUS EVACUANT ENEMA SOLUTION CONTAINING 15 TO 35% BY WEIGHT OF SORBITOL AND A NONTOXIC SALT OF DIOCTYL SULFOSUCCINIC ACID IN DISTILLED WATER.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US685430A US2992970A (en) | 1957-09-23 | 1957-09-23 | Aqueous sorbitol enema solution and method of using same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US685430A US2992970A (en) | 1957-09-23 | 1957-09-23 | Aqueous sorbitol enema solution and method of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
US2992970A true US2992970A (en) | 1961-07-18 |
Family
ID=24752177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US685430A Expired - Lifetime US2992970A (en) | 1957-09-23 | 1957-09-23 | Aqueous sorbitol enema solution and method of using same |
Country Status (1)
Country | Link |
---|---|
US (1) | US2992970A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3275509A (en) * | 1963-04-24 | 1966-09-27 | Robert L Rowan | Method for treating intestinal disorders with a silicone composition enema |
US4201706A (en) * | 1978-09-22 | 1980-05-06 | Burton, Parsons & Company, Inc. | Treatment of corneal edema |
US20140107197A1 (en) * | 2007-12-07 | 2014-04-17 | Ferring International Center S.A. | Pharmaceutical composition |
EP2865371A1 (en) | 2013-10-22 | 2015-04-29 | Disphar International B.V. | Fast dissolving granules |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2721825A (en) * | 1952-08-11 | 1955-10-25 | Cutter Lab | Irrigation fluid for cystoscopy and transurethral prostatectomy |
-
1957
- 1957-09-23 US US685430A patent/US2992970A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2721825A (en) * | 1952-08-11 | 1955-10-25 | Cutter Lab | Irrigation fluid for cystoscopy and transurethral prostatectomy |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3275509A (en) * | 1963-04-24 | 1966-09-27 | Robert L Rowan | Method for treating intestinal disorders with a silicone composition enema |
US4201706A (en) * | 1978-09-22 | 1980-05-06 | Burton, Parsons & Company, Inc. | Treatment of corneal edema |
US20140107197A1 (en) * | 2007-12-07 | 2014-04-17 | Ferring International Center S.A. | Pharmaceutical composition |
EP2865371A1 (en) | 2013-10-22 | 2015-04-29 | Disphar International B.V. | Fast dissolving granules |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huggins et al. | Surgery of the adrenals | |
Foss et al. | Oral methyltestosterone and jaundice | |
US2992970A (en) | Aqueous sorbitol enema solution and method of using same | |
Davies | The history of syphilis in Uganda | |
FRIEDMAN et al. | THE HYPERTENSIVE EFFECT OF COMPOUND FACETATE (17-OH-CORTICOSTERONE-21-ACETATE) IN THfi RAT | |
Smith | Severe anaphylactic reaction after a soap enema. | |
Noble et al. | Lithosperm-Like Action of Certain Quinones | |
McGeorge et al. | Observations on the properties of S-methyl iso-thiourea sulphate, with particular reference to the circulatory effects | |
Lauber et al. | Toxicity of the Mucigogue, eugenol, administered by stomach tube to dogs | |
Wilcox | Pharmocology and Therapeutics | |
Seelig | Localized gangrene following the hypodermic administration of calcium chlorid | |
Starr | Sodium dextrothyroxine and sodium levothyroxine: results of their use in an athyreotic patient with angina pectoris and hypercholesteremia | |
Simpson et al. | The excretion of synthetic oestrogens as ethereal sulphates and monoglucuronides in the rabbit and in man | |
US1932886A (en) | Therapeutic agent | |
Chopra et al. | Carbon Tetrachloride in Pharmacology and Therapeutics | |
US2486937A (en) | Digitalis therapy | |
Marshall et al. | The Pharmacology of the Chlor-Hydrins: a Contribution to the Study of the Relation between Chemical Constitution and Physiological Action | |
ROBINSON et al. | THE TREATMENT OF ACUTE ALCOHOLISM: WITH TEN PER CENT CARBON DIOXIDE AND NINETY PER CENT OXYGEN INHALATION | |
Milch | Local anesthesia in the treatment of visceral and serous pains | |
Morlock | Chronic Pneumothorax Treated by Intra-pleural Injection of Silver Nitrate | |
Upcott | chloroform. Under hedonal, although perception | |
Goodwin | The Hospital treatment of diseases of the heart and lungs | |
Heard | CLINICAL EXPERIENCES WITH AVERTIN ANÆSTHESIA | |
WILDER | III. APPLICATION IN INTERNAL MEDICINE | |
from Pethidine | Current opics, Etc. |